These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 29909414)

  • 1. The Change in Neutrophil Lymphocyte Ratio from the First to the Last Repeat Prostate Biopsy Proposed as a Marker of Carcinogenesis.
    Hashimoto M; Matsumura N; Ohzeki T; Hongo S; Sugimoto K; Shimizu N; Mori Y; Minami T; Nozawa M; Nose K; Tahara H; Yoshimura K; Uemura H
    Urol Int; 2018; 101(1):74-79. PubMed ID: 29909414
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Predictive Value of the Platelet-To-Lymphocyte Ratio in Diagnosis of Prostate Cancer.
    Yuksel OH; Urkmez A; Akan S; Yldirim C; Verit A
    Asian Pac J Cancer Prev; 2015; 16(15):6407-12. PubMed ID: 26434851
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association of the neutrophil-to-lymphocyte ratio and prostate cancer detection rates in patients via contemporary multi-core prostate biopsy.
    Oh JJ; Kwon O; Lee JK; Byun SS; Lee SE; Lee S; Hong SK
    Asian J Androl; 2016; 18(6):937-941. PubMed ID: 26470836
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Predictive value of neutrophil-to-lymphocyte ratio in diagnosis of prostate cancer among men who underwent template-guided prostate biopsy: A STROBE-compliant study.
    Huang TB; Mao SY; Lu SM; Yu JJ; Luan Y; Gu X; Liu H; Zhou GC; Ding XF
    Medicine (Baltimore); 2016 Nov; 95(44):e5307. PubMed ID: 27858908
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Clinical Significance of Neutrophil-to-Lymphocyte Ratio in Patients with Prostate Cancer].
    Naito H; Sugimoto M; Taketa S; Kakehi Y
    Hinyokika Kiyo; 2017 Feb; 63(2):63-67. PubMed ID: 28264535
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neutrophil-to-lymphocyte ratio predicts prostatic carcinoma in men undergoing needle biopsy.
    Kawahara T; Fukui S; Sakamaki K; Ito Y; Ito H; Kobayashi N; Izumi K; Yokomizo Y; Miyoshi Y; Makiyama K; Nakaigawa N; Yamanaka T; Yao M; Miyamoto H; Uemura H
    Oncotarget; 2015 Oct; 6(31):32169-76. PubMed ID: 26359354
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The values of neutrophil-lymphocyte ratio and/or prostate-specific antigen in discriminating real Gleason score ≥ 7 prostate cancer from group of biopsy-based Gleason score ≤ 6.
    Wang H; Gu L; Wu Y; Feng D; Duan J; Wang X; Huang Y; Wu S; Chen J; Luo G; Zhang X
    BMC Cancer; 2017 Sep; 17(1):629. PubMed ID: 28874127
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A novel nomogram combined PIRADS v2 and neutrophil-to-lymphocyte ratio to predict the risk of clinically significant prostate cancer in men with PSA < 10 ng/ml at first biopsy.
    Sun J; Zhang Z; OuYang J
    Urol Oncol; 2020 May; 38(5):401-409. PubMed ID: 31870724
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prostate-specific Antigen Density Variation Rate as a Potential Guideline Parameter for Second Prostate Cancer Detection Biopsy.
    Xie GS; Lyv JX; Li G; Yan CY; Hou JQ; Pu JX; Ding X; Huang YH
    Chin Med J (Engl); 2016 Aug; 129(15):1800-4. PubMed ID: 27453228
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Can prostate specific antigen derivatives and pathological parameters predict significant change in expectant management criteria for prostate cancer?
    Khan MA; Carter HB; Epstein JI; Miller MC; Landis P; Walsh PW; Partin AW; Veltri RW
    J Urol; 2003 Dec; 170(6 Pt 1):2274-8. PubMed ID: 14634395
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Validation of the Effectiveness of Neutrophil-to-lymphocyte Ratio (NLR) as a Predictive Factor in Patients Undergoing Prostate Biopsy With Prostate Specific Antigen (PSA) Between 4.0 and 10.0 ng/ml.
    Masuda H; Mikami K; Otsuka K; Hou K; Suyama T; Araki K; Kojima S; Naya Y
    In Vivo; 2021; 35(3):1641-1646. PubMed ID: 33910847
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Optimal predictors of prostate cancer on repeat prostate biopsy: a prospective study of 1,051 men.
    Djavan B; Zlotta A; Remzi M; Ghawidel K; Basharkhah A; Schulman CC; Marberger M
    J Urol; 2000 Apr; 163(4):1144-8; discussion 1148-9. PubMed ID: 10737484
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neutrophil-to-lymphocyte and neutrophil-to-monocyte rates in the decision for a prostate re-biopsy in patients with a previous benign pathology and consistently 2,5-10 ng/ml PSA value.
    Ceylan Y; Günlüsoy B; Degirmenci T; Bolat D; Kozacioglu Z; Vardar E; Topçu YK; Polat S
    Arch Esp Urol; 2016 Nov; 69(9):627-635. PubMed ID: 27845694
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Utility of PCA3 in patients undergoing repeat biopsy for prostate cancer.
    Wu AK; Reese AC; Cooperberg MR; Sadetsky N; Shinohara K
    Prostate Cancer Prostatic Dis; 2012 Mar; 15(1):100-5. PubMed ID: 22042252
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neutrophil, Platelets, and Eosinophil to Lymphocyte Ratios Predict Gleason Score Upgrading in Low-Risk Prostate Cancer Patients.
    Ferro M; Musi G; Serino A; Cozzi G; Mistretta FA; Costa B; Bianchi R; Cordima G; Luzzago S; Di Trapani E; Tagliabue E; Vartolomei MD; Terracciano D; Cassatella MC; Salvatici M; Conti A; Sandri MT; Cioffi A; Turetti M; Catellani M; Bottero D; Matei DV; Mirone V; de Cobelli O
    Urol Int; 2019; 102(1):43-50. PubMed ID: 30408799
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Value of prostate volume measurement using transabdominal ultrasonography for the improvement of prostate-speci fi c antigen-based cancer detection.
    Kobayashi T; Kawahara T; Nishizawa K; Ogura K; Mitsumori K; Ide Y
    Int J Urol; 2005 Oct; 12(10):881-5. PubMed ID: 16323981
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prostate-specific antigen (PSA) isoform p2PSA significantly improves the prediction of prostate cancer at initial extended prostate biopsies in patients with total PSA between 2.0 and 10 ng/ml: results of a prospective study in a clinical setting.
    Guazzoni G; Nava L; Lazzeri M; Scattoni V; Lughezzani G; Maccagnano C; Dorigatti F; Ceriotti F; Pontillo M; Bini V; Freschi M; Montorsi F; Rigatti P
    Eur Urol; 2011 Aug; 60(2):214-22. PubMed ID: 21482022
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Importance of neutrophil/lymphocyte ratio in prediction of PSA recurrence after radical prostatectomy.
    Gazel E; Tastemur S; Acikgoz O; Yigman M; Olcucuoglu E; Camtosun A; Ceylan C; Ates C
    Asian Pac J Cancer Prev; 2015; 16(5):1813-6. PubMed ID: 25773829
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Neutrophil-to-Lymphocyte Ratio before Repeat Prostate Needle Biopsy for Predicting Prostate Cancer.
    Maeda Y; Kawahara T; Kumano Y; Ohtaka M; Kondo T; Mochizuki T; Hattori Y; Teranishi J; Miyoshi Y; Yumura Y; Miyamoto H; Yao M; Uemura H
    Urol Int; 2016; 96(1):123-4. PubMed ID: 26669562
    [No Abstract]   [Full Text] [Related]  

  • 20. Predictive Value of Neutrophil to Lymphocyte Ratio in the Diagnosis of Significant Prostate Cancer at Initial Biopsy: A Comparison with Free Percent Prostate Specific Antigen, Prostate Specific Antigen Density and Primary Circulating Prostate Cells.
    Murray NP; Fuentealba C; Reyes E; Lopez MA; Salazar A; Minzer S; Munoz L; Orrego S; Guzman E; Arzeno L
    Asian Pac J Cancer Prev; 2019 Nov; 20(11):3385-3389. PubMed ID: 31759363
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.